PRNewsWire
20 May 2026, 20:20 UTC · 17w ago
Verdict
Headline takes no side. We score BMRN +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
BioMarin's Phase 3 study for VOXZOGO in children with hypochondroplasia met its primary endpoint, showing a statistically significant increase in annualized growth velocity of 2.33 cm/yr over placebo.
More positive than 99% of claims this week
BioMarin plans to submit a supplemental New Drug Application (sNDA) to the FDA in the third quarter of 2026, followed by EMA and other regional filings.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 85% of claims this week
The study reported no new safety signals, with findings consistent with the established safety profile for VOXZOGO in achondroplasia.
More positive than 62% of claims this week
The study demonstrated statistically significant improvements in standing height, height Z-score, and arm span compared to placebo.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company announced positive Phase 3 pivotal study results for VOXZOGO in children with hypochondroplasia, exceeding expectations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
12h ago
+27.4%
Price agrees with the score
$63.94 vs $50.20 close before publication (May 20) · not market-adjusted
BMRN chart →
